These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 35070771)
1. Review of barriers and interventions to promote treatment engagement for pediatric attention deficit hyperactivity disorder care. Baweja R; Soutullo CA; Waxmonsky JG World J Psychiatry; 2021 Dec; 11(12):1206-1227. PubMed ID: 35070771 [TBL] [Abstract][Full Text] [Related]
2. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder. Foy JM; Earls MF Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972 [TBL] [Abstract][Full Text] [Related]
3. Engagement Barriers to Behavior Therapy for Adolescent ADHD. Sibley MH; Link K; Torres Antunez G; Greenwood L J Clin Child Adolesc Psychol; 2023; 52(6):834-849. PubMed ID: 35084265 [TBL] [Abstract][Full Text] [Related]
4. Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research. Richardson M; Moore DA; Gwernan-Jones R; Thompson-Coon J; Ukoumunne O; Rogers M; Whear R; Newlove-Delgado TV; Logan S; Morris C; Taylor E; Cooper P; Stein K; Garside R; Ford TJ Health Technol Assess; 2015 Jun; 19(45):1-470. PubMed ID: 26129788 [TBL] [Abstract][Full Text] [Related]
5. What stops practitioners discussing medication breaks in children and adolescents with ADHD? Identifying barriers through theory-driven qualitative research. Ibrahim K; Donyai P Atten Defic Hyperact Disord; 2018 Dec; 10(4):273-283. PubMed ID: 29982921 [TBL] [Abstract][Full Text] [Related]
6. Treatments for child and adolescent attention deficit hyperactivity disorder in low and middle-income countries: A narrative review. Pipe A; Ravindran N; Paric A; Patterson B; Van Ameringen M; Ravindran AV Asian J Psychiatr; 2022 Oct; 76():103232. PubMed ID: 35987096 [TBL] [Abstract][Full Text] [Related]
7. Effectiveness of a telehealth service delivery model for treating attention-deficit/hyperactivity disorder: a community-based randomized controlled trial. Myers K; Vander Stoep A; Zhou C; McCarty CA; Katon W J Am Acad Child Adolesc Psychiatry; 2015 Apr; 54(4):263-74. PubMed ID: 25791143 [TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of pharmacotherapies for attention-deficit hyperactivity disorder: a systematic literature review. Wu EQ; Hodgkins P; Ben-Hamadi R; Setyawan J; Xie J; Sikirica V; Du EX; Yan SY; Erder MH CNS Drugs; 2012 Jul; 26(7):581-600. PubMed ID: 22712698 [TBL] [Abstract][Full Text] [Related]
9. Barriers to evidence-based treatment for children with attention-deficit/hyperactivity disorder. Corkum P; Bessey M; McGonnell M; Dorbeck A Atten Defic Hyperact Disord; 2015 Mar; 7(1):49-74. PubMed ID: 25055885 [TBL] [Abstract][Full Text] [Related]
10. Treatment of Attention-Deficit/Hyperactivity Disorder in Adolescents: A Systematic Review. Chan E; Fogler JM; Hammerness PG JAMA; 2016 May; 315(18):1997-2008. PubMed ID: 27163988 [TBL] [Abstract][Full Text] [Related]
11. [International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder]. Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V Z Kinder Jugendpsychiatr Psychother; 2021 Jan; 50(1):54-67. PubMed ID: 34397296 [TBL] [Abstract][Full Text] [Related]
12. Can Neurocognitive Outcomes Assist Measurement-Based Care for Children with Attention-Deficit/Hyperactivity Disorder? A Systematic Review and Meta-Analyses of the Relationships Among the Changes in Neurocognitive Functions and Clinical Outcomes of Attention-Deficit/Hyperactivity Disorder in Pharmacological and Cognitive Training Interventions. Lee S; Hill TR; Johnson B; Testa R; Priya V; Spencer-Smith M; Coghill D J Child Adolesc Psychopharmacol; 2022 Jun; 32(5):250-277. PubMed ID: 35704876 [TBL] [Abstract][Full Text] [Related]
13. Social skills training for attention deficit hyperactivity disorder (ADHD) in children aged 5 to 18 years. Storebø OJ; Elmose Andersen M; Skoog M; Joost Hansen S; Simonsen E; Pedersen N; Tendal B; Callesen HE; Faltinsen E; Gluud C Cochrane Database Syst Rev; 2019 Jun; 6(6):CD008223. PubMed ID: 31222721 [TBL] [Abstract][Full Text] [Related]
14. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Garnock-Jones KP; Keating GM Paediatr Drugs; 2009; 11(3):203-26. PubMed ID: 19445548 [TBL] [Abstract][Full Text] [Related]
15. International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. Özgen H; Spijkerman R; Noack M; Holtmann M; Schellekens ASA; van de Glind G; Banaschewski T; Barta C; Begeman A; Casas M; Crunelle CL; Daigre Blanco C; Dalsgaard S; Demetrovics Z; den Boer J; Dom G; Eapen V; Faraone SV; Franck J; González RA; Grau-López L; Groenman AP; Hemphälä M; Icick R; Johnson B; Kaess M; Kapitány-Fövény M; Kasinathan JG; Kaye SS; Kiefer F; Konstenius M; Levin FR; Luderer M; Martinotti G; Matthys FIA; Meszaros G; Moggi F; Munasur-Naidoo AP; Post M; Rabinovitz S; Ramos-Quiroga JA; Sala R; Shafi A; Slobodin O; Staal WG; Thomasius R; Truter I; van Kernebeek MW; Velez-Pastrana MC; Vollstädt-Klein S; Vorspan F; Young JT; Yule A; van den Brink W; Hendriks V Eur Addict Res; 2020; 26(4-5):223-232. PubMed ID: 32634814 [TBL] [Abstract][Full Text] [Related]
16. The cost-effectiveness of treatments for attention deficit-hyperactivity disorder and autism spectrum disorder in children and adolescents: a systematic review. Sampaio F; Feldman I; Lavelle TA; Skokauskas N Eur Child Adolesc Psychiatry; 2022 Nov; 31(11):1655-1670. PubMed ID: 33751229 [TBL] [Abstract][Full Text] [Related]
17. Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder. Daley D; Van Der Oord S; Ferrin M; Cortese S; Danckaerts M; Doepfner M; Van den Hoofdakker BJ; Coghill D; Thompson M; Asherson P; Banaschewski T; Brandeis D; Buitelaar J; Dittmann RW; Hollis C; Holtmann M; Konofal E; Lecendreux M; Rothenberger A; Santosh P; Simonoff E; Soutullo C; Steinhausen HC; Stringaris A; Taylor E; Wong ICK; Zuddas A; Sonuga-Barke EJ J Child Psychol Psychiatry; 2018 Sep; 59(9):932-947. PubMed ID: 29083042 [TBL] [Abstract][Full Text] [Related]
18. Individualised short-term therapy for adolescents impaired by attention-deficit/hyperactivity disorder despite previous routine care treatment (ESCAadol)-Study protocol of a randomised controlled trial within the consortium ESCAlife. Geissler J; Jans T; Banaschewski T; Becker K; Renner T; Brandeis D; Döpfner M; Dose C; Hautmann C; Holtmann M; Jenkner C; Millenet S; Romanos M Trials; 2018 Apr; 19(1):254. PubMed ID: 29703226 [TBL] [Abstract][Full Text] [Related]